tradingkey.logo

Sinovac Biotech Ltd

SVA
0.0000.00%
Close 01/23, 16:00ETQuotes delayed by 15 min
--Market Cap
--P/E TTM

Sinovac Biotech Ltd

0.0000.00%

More Details of Sinovac Biotech Ltd Company

Sinovac Biotech Ltd (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, hand foot and mouth disease (HFMD), seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine.

Sinovac Biotech Ltd Info

Ticker SymbolSVA
Company nameSinovac Biotech Ltd
IPO dateNov 13, 2009
CEOYin (Weidong)
Number of employees3037
Security typeOrdinary Share
Fiscal year-endNov 13
AddressNo. 39 Shangdi Xi Road
CityBEIJING
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code100085
Phone861082890088
Websitehttp://www.sinovac.com/
Ticker SymbolSVA
IPO dateNov 13, 2009
CEOYin (Weidong)

Company Executives of Sinovac Biotech Ltd

Name
Name/Position
Position
Shareholding
Change
Mr. Weidong Yin
Mr. Weidong Yin
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
6.36M
--
Mr. Shan Fu
Mr. Shan Fu
Director
Director
--
--
Mr. Qiang Gao
Mr. Qiang Gao
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Ms. Jing Li
Ms. Jing Li
Vice President - Quality and Production
Vice President - Quality and Production
--
--
Ms. Guang (Helen) Yang
Ms. Guang (Helen) Yang
Chief Business Officer
Chief Business Officer
--
--
Dr. Chiang Li
Dr. Chiang Li
Independent Director
Independent Director
--
--
Mr. Shuge Jiao
Mr. Shuge Jiao
Director
Director
--
--
Mr. Yumin Qiu
Mr. Yumin Qiu
Director
Director
--
--
Mr. Yu Wang
Mr. Yu Wang
Director
Director
--
--
Ms. Rui-Ping Xiao
Ms. Rui-Ping Xiao
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Weidong Yin
Mr. Weidong Yin
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
6.36M
--
Mr. Shan Fu
Mr. Shan Fu
Director
Director
--
--
Mr. Qiang Gao
Mr. Qiang Gao
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Ms. Jing Li
Ms. Jing Li
Vice President - Quality and Production
Vice President - Quality and Production
--
--
Ms. Guang (Helen) Yang
Ms. Guang (Helen) Yang
Chief Business Officer
Chief Business Officer
--
--
Dr. Chiang Li
Dr. Chiang Li
Independent Director
Independent Director
--
--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Mainland China
381.06M
85.01%
Foreign countries
67.21M
14.99%
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sat, Sep 6
Updated: Sat, Sep 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
1Globe Capital, L.L.C.
20.84%
SAIF Advisors Limited
17.95%
Yin (Weidong)
10.59%
CDH Utopia Ltd
9.99%
Vivo Capital, LLC
9.83%
Other
30.81%
Shareholders
Shareholders
Proportion
1Globe Capital, L.L.C.
20.84%
SAIF Advisors Limited
17.95%
Yin (Weidong)
10.59%
CDH Utopia Ltd
9.99%
Vivo Capital, LLC
9.83%
Other
30.81%
Shareholder Types
Shareholders
Proportion
Corporation
40.57%
Private Equity
22.48%
Individual Investor
10.59%
Venture Capital
9.83%
Hedge Fund
2.23%
Investment Advisor
0.64%
Pension Fund
0.11%
Investment Advisor/Hedge Fund
0.07%
Research Firm
0.04%
Other
13.44%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
40
21.27M
35.41%
-236.72K
2025Q3
44
21.27M
35.41%
+1.17M
2025Q2
44
50.49M
80.19%
+7.31M
2025Q1
43
41.31M
49.65%
+4.02M
2024Q4
43
35.46M
35.59%
-13.70M
2024Q3
45
47.33M
47.51%
-1.85M
2024Q2
45
48.79M
48.97%
+2.33M
2024Q1
45
46.23M
46.40%
+10.46M
2023Q4
44
35.53M
35.68%
-8.81M
2023Q3
46
44.32M
44.54%
-16.57K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
1Globe Capital, L.L.C.
12.52M
20.84%
--
--
Jul 07, 2025
SAIF Advisors Limited
10.78M
17.95%
--
--
Jul 10, 2025
Yin (Weidong)
6.36M
10.59%
--
--
Jul 10, 2025
CDH Utopia Ltd
6.00M
9.99%
--
--
Jul 07, 2025
Vivo Capital, LLC
5.90M
9.83%
--
--
Sep 30, 2025
Advantech Capital LP
5.85M
9.74%
--
--
Jul 08, 2025
OrbiMed Advisors, LLC
2.72M
4.53%
--
--
Sep 30, 2025
Renaissance Technologies LLC
1.31M
2.19%
--
--
Sep 30, 2025
Neumann Advisory Hong Kong Limited
315.59K
0.53%
--
--
Sep 30, 2025
California Public Employees' Retirement System
68.73K
0.11%
--
--
Sep 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
SPDR SSGA US Small Cap Low Volatility Index ETF
0%
SPDR S&P Emerging Markets Small Cap ETF
0%
SPDR Portfolio Emerging Markets ETF
0%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proportion0%
SPDR S&P Emerging Markets Small Cap ETF
Proportion0%
SPDR Portfolio Emerging Markets ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
KeyAI